Kamax
A new real-time imaging system, based on the polarization of light, for the diagnosis of cancerous pathologies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
€440k | Early VC | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 4 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | 2 % | 4 % | 2 % |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | 1 % | 2 % | 1 % |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Kamax, founded in 2013 in Limoges, specializes in advanced polarization imaging technology derived from research at CNRS XLIM and the University of Limoges. This innovative technology allows for the translation and quantification of biological modifications through detailed imaging, making it highly valuable for hospitals, clinical laboratories, and research institutions. Kamax's solutions are particularly beneficial in the cosmetic industry, where they aid in the development and characterization of new products. The company operates in the medical imaging and cosmetic research markets, serving clients who require precise, comprehensive, and rapid diagnostic capabilities. Kamax generates revenue through the sale and licensing of its imaging technology and related services.
Keywords: Polarization imaging, biological modifications, diagnostics, research, cosmetic industry, CNRS XLIM, University of Limoges, medical imaging, technology licensing, innovation.